[Lu-177]-PNT2002 + Abiraterone + Enzalutamide
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration-Resistant Prostate Cancer
Conditions
Metastatic Castration-Resistant Prostate Cancer
Trial Timeline
Feb 25, 2021 → Mar 1, 2028
NCT ID
NCT04647526About [Lu-177]-PNT2002 + Abiraterone + Enzalutamide
[Lu-177]-PNT2002 + Abiraterone + Enzalutamide is a phase 3 stage product being developed by Eli Lilly for Metastatic Castration-Resistant Prostate Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04647526. Target conditions include Metastatic Castration-Resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration-Resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04647526 | Phase 3 | Active |
Competing Products
20 competing products in Metastatic Castration-Resistant Prostate Cancer